PART I – FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Unaudited interim financials for H1 2020 report a **$22.7 million net loss**, reduced cash, and a strategic pivot to MLE-301 development [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets decreased to **$57.1 million** by June 30, 2020, primarily due to a reduction in cash and cash equivalents Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2020 | December 31, 2019 | | :--- | :--- | :--- | | Cash and cash equivalents | $50,312 | $62,478 | | Total current assets | $54,072 | $71,132 | | Total assets | $57,132 | $74,970 | | Total current liabilities | $10,086 | $12,520 | | Total liabilities | $12,188 | $15,099 | | Total stockholders' equity | $44,944 | $59,871 | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss for Q2 2020 was **$10.7 million**, and **$22.7 million** for H1 2020, primarily due to increased R&D expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $6,466 | $5,981 | $14,006 | $12,185 | | General and administrative | $4,138 | $4,179 | $8,733 | $8,632 | | Loss from operations | $10,604 | $10,160 | $22,739 | $20,817 | | Net loss | $(10,672) | $(9,871) | $(22,670) | $(20,237) | | Net loss per share | $(0.56) | $(0.74) | $(1.21) | $(1.51) | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations for H1 2020 was **$18.0 million**, with a **$12.5 million** decrease in total cash Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2020 | 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | $(18,030) | $(21,174) | | Net cash (used in) provided by investing activities | $(26) | $4,108 | | Net cash provided by (used in) financing activities | $5,513 | $(38) | | Net decrease in cash, cash equivalents and restricted cash | $(12,495) | $(17,139) | | Cash, cash equivalents and restricted cash at end of period | $51,017 | $56,631 | [Notes to Unaudited Interim Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Interim%20Consolidated%20Financial%20Statements) Notes detail program discontinuations, associated **$3.1 million** closeout costs and **$1.1 million** termination benefits, and a **$51.0 million** cash position - The company discontinued the development of livoletide for PWS in April 2020, recording **$3.1 million** in associated costs in Q2 2020[22](index=22&type=chunk) - Following the PWS program discontinuation, the company eliminated approximately **30% of its workforce**, resulting in **$1.1 million** in one-time termination benefits in Q2 2020[23](index=23&type=chunk) - In June 2020, the company ceased investing in the development of nevanimibe for CAH based on an interim data review[24](index=24&type=chunk) - As of June 30, 2020, the company had **$51.0 million** in cash, cash equivalents, and restricted cash, which management believes is sufficient to fund operations for at least 12 months[27](index=27&type=chunk)[31](index=31&type=chunk) - In March 2020, the company sold 719,400 shares of common stock under its "at-the-market" (ATM) equity distribution agreement for net proceeds of approximately **$5.7 million**[30](index=30&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the strategic shift to MLE-301, increased R&D expenses, and a **$51.0 million** cash position projected to fund operations into 2022 [Overview and COVID-19 Update](index=22&type=section&id=Overview%20and%20COVID-19%20Update) The company refocused on MLE-301 development with a Phase 1 trial planned for Q3 2020, initiated a strategic review, and monitors COVID-19 impacts - The company's primary focus is now on developing MLE-301 for vasomotor symptoms (VMS) in menopausal women, with a Phase 1 trial expected to start in Q3 2020[78](index=78&type=chunk)[79](index=79&type=chunk) - Development of livoletide for PWS was discontinued in April 2020, and investment in nevanimibe for CAH ceased in June 2020[80](index=80&type=chunk)[82](index=82&type=chunk) - The company has engaged SVB Leerink to support a strategic review process to maximize stockholder value[84](index=84&type=chunk) - The COVID-19 pandemic is being closely monitored, but the company expects to have an adequate supply of MLE-301 for its planned Phase 1 trial[86](index=86&type=chunk)[87](index=87&type=chunk) [Results of Operations](index=24&type=section&id=Results%20of%20Operations) R&D expenses increased to **$6.5 million** in Q2 2020 and **$14.0 million** in H1 2020, driven by MLE-301 and closeout costs Comparison of Operating Results (in thousands) | Metric | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $6,466 | $5,981 | $14,006 | $12,185 | | General and administrative | $4,138 | $4,179 | $8,733 | $8,632 | | Net loss | $(10,672) | $(9,871) | $(22,670) | $(20,237) | - The increase in Q2 2020 R&D expense was driven by a **$0.5 million** increase in preclinical/clinical costs (mainly for MLE-301) and a **$0.3 million** increase in compensation due to severance, partially offset by a **$0.2 million** decrease in stock-based compensation[100](index=100&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk) - The increase in H1 2020 R&D expense was primarily due to a **$1.9 million** rise in preclinical/clinical development costs related to MLE-301 and livoletide program closeout activities[107](index=107&type=chunk)[110](index=110&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds **$51.0 million** in cash, projected to fund operations into 2022, after using **$18.0 million** in H1 2020 operations - The company had cash, cash equivalents, and restricted cash of **$51.0 million** as of June 30, 2020[119](index=119&type=chunk) - Management projects the current cash position is sufficient to fund operations into 2022, based on current plans[90](index=90&type=chunk)[119](index=119&type=chunk) - In March 2020, the company sold 719,400 shares under its ATM agreement for net proceeds of approximately **$5.7 million**[118](index=118&type=chunk) - Net cash used in operating activities for the first six months of 2020 was **$18.0 million**, compared to **$21.2 million** for the same period in 2019[111](index=111&type=chunk)[112](index=112&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exempt from market risk disclosures as it qualifies as a smaller reporting company - The company is not required to provide disclosures about market risk as it qualifies as a smaller reporting company[127](index=127&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 30, 2020, with no material changes in internal controls - Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2020[128](index=128&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[129](index=129&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) The company is defending against shareholder derivative and class action lawsuits inherited from OvaScience, unable to estimate potential losses - The company is defending against a purported shareholder derivative action (Cima v. Dipp) and a shareholder class action lawsuit (Dahhan v. OvaScience, Inc.) related to the former operations of OvaScience[132](index=132&type=chunk)[133](index=133&type=chunk) - A third shareholder derivative complaint (Chiu v. Dipp) is currently stayed pending the resolution of the Dahhan Action[134](index=134&type=chunk) - The company believes the complaints are without merit but cannot estimate potential losses at this time[132](index=132&type=chunk)[133](index=133&type=chunk)[134](index=134&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) Significant risks include operating losses, capital needs, dependence on MLE-301, COVID-19 impacts, intense competition, and reliance on third parties - The company has a history of significant operating losses (**$231.3 million** accumulated deficit as of June 30, 2020) and expects to incur substantial losses for the foreseeable future[137](index=137&type=chunk) - Future success is highly dependent on the successful clinical development, regulatory approval, and commercialization of MLE-301, as previous lead candidates have been discontinued[155](index=155&type=chunk)[156](index=156&type=chunk) - The COVID-19 pandemic poses a material risk to business operations, clinical trial timelines, and the ability to access capital[305](index=305&type=chunk)[308](index=308&type=chunk) - The company relies on third-party CMOs for manufacturing and CROs for clinical trials, making it dependent on their performance and compliance with regulations like cGMP and GCP[291](index=291&type=chunk)[300](index=300&type=chunk) - The company faces substantial competition from major pharmaceutical and biotech companies with greater resources, such as Astellas and KaNDy Therapeutics in the VMS space[177](index=177&type=chunk)[179](index=179&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=90&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity securities were sold, nor were any issuer purchases made during Q2 2020 - There were no sales of unregistered securities during the three months ended June 30, 2020[346](index=346&type=chunk) [Defaults Upon Senior Securities](index=90&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable as the company has no defaults upon senior securities to report - Not applicable[348](index=348&type=chunk) [Mine Safety Disclosures](index=90&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[349](index=349&type=chunk) [Other Information](index=90&type=section&id=Item%205.%20Other%20Information) No other information is reported for this period - Not applicable[350](index=350&type=chunk) [Exhibits](index=91&type=section&id=Item%206.%20Exhibits) Exhibits include amendments to equity incentive plans and CEO/CFO certifications required by Sarbanes-Oxley - The report includes amendments to the 2012 and 2019 Equity Incentive Plans[352](index=352&type=chunk) - Certifications by the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act are filed as exhibits[352](index=352&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 10-Q _____________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ ...

Pipeline Highlights - Millendo Therapeutics is developing Livoletide for Prader-Willi Syndrome (PWS), with topline data expected in early 2Q20[5, 63] - The company is also developing Nevanimibe for classic congenital adrenal hyperplasia (CAH), with topline data from cohort 1 expected in 2H20[5, 63] - MLE-301, a preclinical program for vasomotor symptoms (VMS) associated with menopause, is expected to enter first-in-human trials in 2H20[5, 63] Livoletide for Prader-Willi Syndrome (PWS) - PWS affects approximately 1 in 15,000 births due to a spontaneous genetic defect[12] - A Phase 2a clinical trial showed clinically meaningful decreases in Hyperphagia Questionnaire (HQ) scores with livoletide[18, 19] - In the Phase 2a trial, 65% of livoletide-treated patients showed a ≥ 4-point decrease in HQ score[25] - The pivotal Phase 2b study (ZEPHYR) is fully recruited with 158 patients[33] Nevanimibe for Congenital Adrenal Hyperplasia (CAH) - CAH affects approximately 15,000 to 18,000 people in the U S and ~40,000 in Europe[40] - A Phase 2a study demonstrated activity through reductions in 17-OHP, with 70% of subjects experiencing a decrease of ≥ 50% during at least one treatment period[46] - A Phase 2b clinical trial in CAH is ongoing, with topline results from cohort 1 anticipated in 2H20[5, 53] Financial Position - The company has financial strength, with current cash position expected to support capital needs into 2022[5] - As of December 31, 2019, Millendo had a cash balance of $63.5 million[63]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _______________________________________________________________________________________________________________________________ FORM 10-K _______________________________________________________________________________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION ...

PART I [Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Millendo Therapeutics reported a **$31.9 million net loss** for the nine months ended September 30, 2019, with **$48.3 million in cash** and the adoption of ASC 842 [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Total assets decreased to **$58.5 million** by September 30, 2019, driven by reduced cash, while liabilities increased and stockholders' equity declined due to net loss Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2019 | Dec 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $47,151 | $73,286 | | Total current assets | $53,652 | $83,422 | | Total assets | $58,479 | $84,074 | | **Liabilities & Equity** | | | | Total current liabilities | $10,513 | $9,817 | | Total liabilities | $13,650 | $10,952 | | Total stockholders' equity | $44,829 | $73,122 | | Total liabilities and stockholders' equity | $58,479 | $84,074 | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company reported no revenue, with a **net loss of $11.6 million** for Q3 2019 and **$31.9 million** for the nine months, driven by increased R&D and G&A expenses Operating Results (in thousands, except per share data) | Metric | Q3 2019 | Q3 2018 | 9 Months 2019 | 9 Months 2018 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $7,308 | $3,871 | $19,493 | $9,840 | | General and administrative | $4,443 | $3,935 | $13,075 | $7,340 | | Loss from operations | $11,751 | $7,806 | $32,568 | $17,180 | | Net loss | $(11,632) | $(7,891) | $(31,869) | $(17,319) | | Net loss per share, basic and diluted | $(0.87) | $(10.61) | $(2.38) | $(23.43) | [Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Consolidated%20Statements%20of%20Convertible%20Preferred%20Stock,%20Redeemable%20Noncontrolling%20Interest%20and%20Stockholders'%20Equity%20(Deficit)) Total stockholders' equity decreased to **$44.8 million** by September 30, 2019, primarily due to a **$31.9 million net loss**, partially offset by stock-based compensation Changes in Stockholders' Equity (Nine Months Ended Sep 30, 2019, in thousands) | Description | Amount | | :--- | :--- | | Balance at January 1, 2019 | $73,122 | | Net loss | $(31,869) | | Stock-based compensation expense | $3,130 | | Exercise of stock options & warrants | $471 | | Other adjustments | $(25) | | Balance at September 30, 2019 | $44,829 | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$29.5 million** for the nine months ended September 30, 2019, resulting in a **$25.4 million net decrease** in cash, bringing the period-end balance to **$48.3 million** Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | $(29,531) | $(14,421) | | Net cash provided by (used in) investing activities | $4,021 | $(544) | | Net cash provided by financing activities | $83 | $7,134 | | Net decrease in cash, cash equivalents and restricted cash | $(25,422) | $(7,855) | [Notes to Unaudited Interim Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Interim%20Consolidated%20Financial%20Statements) The notes detail the company's focus on orphan endocrine diseases with key candidates livoletide and nevanimibe, the discontinuation of nevanimibe for Cushing's, **$48.3 million in cash** for liquidity, and the adoption of ASC 842 - The company is a late-stage biopharmaceutical firm focused on orphan endocrine diseases, with key product candidates being **livoletide (PWS)**, **nevanimibe (CAH)**, and **MLE-301 (VMS)**[21](index=21&type=chunk) - In August 2019, the company discontinued its Phase 2 clinical trial and suspended development of **nevanimibe for endogenous Cushing's syndrome (CS)** due to slow patient enrollment[22](index=22&type=chunk) - As of September 30, 2019, the company had **$48.3 million in cash**, cash equivalents, marketable securities, and restricted cash, expected to fund operations through **Q4 2020**[29](index=29&type=chunk)[31](index=31&type=chunk) - The adoption of ASC 842 resulted in the recognition of a **$3.6 million operating lease right-of-use asset** and **$4.5 million operating lease liabilities** as of September 30, 2019[35](index=35&type=chunk)[41](index=41&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses clinical trial advancements for livoletide and nevanimibe, including program updates and the suspension of the Cushing's program, alongside a **$31.9 million net loss** driven by increased R&D, with **$48.3 million in cash** expected to fund operations through **Q4 2020** - The pivotal Phase 2b/3 clinical trial of **livoletide in PWS** is fully recruited for the Phase 2b portion, with topline results expected in **H1 2020**[75](index=75&type=chunk)[77](index=77&type=chunk) - Topline results for **nevanimibe in CAH (Cohort 1)** are now expected in **H2 2020**, a delay from prior estimates[76](index=76&type=chunk)[79](index=79&type=chunk) - In August 2019, the company discontinued its Phase 2 trial and suspended development of **nevanimibe for Cushing's syndrome (CS)** due to slow enrollment, redirecting resources to other programs[80](index=80&type=chunk) R&D Expenses by Program (in thousands) | Program | 9 Months 2019 | 9 Months 2018 | | :--- | :--- | :--- | | Nevanimibe expenses | $2,595 | $3,140 | | Livoletide expenses | $9,881 | $3,192 | | MLE-301 expenses | $1,282 | $— | | Personnel & Other | $5,735 | $3,508 | | **Total** | **$19,493** | **$9,840** | Comparison of Operating Results (Nine Months Ended Sep 30, in thousands) | Item | 2019 | 2018 | Change | | :--- | :--- | :--- | :--- | | Research and development | $19,493 | $9,840 | $9,653 | | General and administrative | $13,075 | $7,340 | $5,735 | | **Net loss** | **$(31,869)** | **$(17,319)** | **$(14,550)** | - The company has an **"at-the-market" (ATM) equity distribution agreement** for up to **$50.0 million**, with no shares issued to date[108](index=108&type=chunk) - As of September 30, 2019, the company had **$48.3 million in cash**, cash equivalents, marketable securities, and restricted cash, expected to fund operations through **Q4 2020** and the **livoletide Phase 2b trial topline results**[109](index=109&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not required for smaller reporting companies, thus no information is provided - Disclosure is not required for smaller reporting companies[120](index=120&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2019, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's **disclosure controls and procedures were effective** as of September 30, 2019[121](index=121&type=chunk) - No material changes to **internal control over financial reporting** occurred during the quarter ended September 30, 2019[122](index=122&type=chunk) PART II — OTHER INFORMATION [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company is defending against multiple shareholder lawsuits inherited from the OvaScience merger, including derivative and class actions, believing them to be without merit - The company is defending against a **shareholder derivative action (Cima v. Dipp)** and a **shareholder class action (Dahhan v. OvaScience)** related to former OvaScience operations[126](index=126&type=chunk)[127](index=127&type=chunk) - A third lawsuit, a **shareholder derivative complaint (Chiu v. Dipp)**, is stayed pending resolution of the Dahhan Action[128](index=128&type=chunk) - For all ongoing legal matters, the company believes the complaints are **without merit** but cannot currently estimate potential losses[126](index=126&type=chunk)[127](index=127&type=chunk)[128](index=128&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including ongoing operating losses, the need for additional capital, clinical development and regulatory approval uncertainties for livoletide and nevanimibe, intense competition, intellectual property limitations, and reliance on third-party manufacturers and CROs - The company has a history of significant operating losses (**$31.9 million** for the nine months ended Sep 30, 2019) and expects substantial future losses, requiring **additional capital**[132](index=132&type=chunk)[140](index=140&type=chunk) - Future success is highly dependent on the successful clinical development, regulatory approval, and commercialization of **livoletide and nevanimibe**[149](index=149&type=chunk) - The company faces substantial competition for its product candidates in **PWS**, **CAH**, and **VMS** from companies with greater resources[168](index=168&type=chunk)[170](index=170&type=chunk)[171](index=171&type=chunk)[172](index=172&type=chunk) - The company relies on **third-party CMOs and CROs** for manufacturing and clinical trials, exposing it to risks of supply delays and performance issues[292](index=292&type=chunk)[301](index=301&type=chunk) - A key intellectual property risk is the **lack of broad composition of matter patent protection for nevanimibe**, potentially limiting competitive barriers[278](index=278&type=chunk) - The company is subject to **ongoing legal proceedings** inherited from the OvaScience merger, potentially incurring substantial costs and diverting management attention[335](index=335&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=111&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company did not sell any unregistered equity securities or repurchase any of its equity securities during the three months ended September 30, 2019 - The company did not sell any unregistered securities during the third quarter of 2019[345](index=345&type=chunk) - The company did not repurchase any of its equity securities during the third quarter of 2019[346](index=346&type=chunk) [Defaults Upon Senior Securities](index=111&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable to the company - Not applicable[347](index=347&type=chunk) [Mine Safety Disclosures](index=111&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[348](index=348&type=chunk) [Other Information](index=113&type=section&id=Item%205.%20Other%20Information) This item is not applicable to the company - Not applicable[349](index=349&type=chunk) [Exhibits](index=113&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including amended employment and consulting agreements, and required CEO and CFO certifications - The report includes several new or amended **management compensatory plans and agreements** as exhibits[351](index=351&type=chunk)[352](index=352&type=chunk) - **CEO and CFO certifications** pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act are filed with the report[351](index=351&type=chunk)

May 2018 Presentation to Corporate Presentation Lorem Ipsum Dolor September 2019 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, expectations or foreca ...

May 2018 Presentation to Corporate Presentation Lorem Ipsum Dolor August 2019 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, expectations or forecasts ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35890 Millendo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45‑1472564 (State or Other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001‑35890 Millendo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45‑1472564 (State or Other ...

May 2018 Presentation to Corporate Presentation Lorem Ipsum Dolor May 2019 Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, beliefs, expectati ...